Gabapentin Capsule
Product Images NDC 60760-741

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-741). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 741 60)

Gaba (Gabapentin 60760 741 60)
This is a description of a Gabapentin medication. It comes in capsule form and is 300mg. The package contains 60 capsules with NDC code 60760-741-60. The medication is manufactured by ScieGen Pharmaceuticals in Hauppauge, NY, and packaged by S, StMaws & Hllary’s in Oro Valley, AZ. The medication is to be stored at a controlled room temperature between 15°C to 30°C (59°F to 86°F).*
FDA Label Image

Figure 1 (Image 01)

Figure 1 (Image 01)
This is a chart of mean pain score over time comparing two groups: one on a fixed dose of Parkod and the other on a placebo or on 3600mg/day of Gabapentin. The pain score is measured on a scale of 0-4. The chart shows the baseline pain score and pain scores at subsequent weeks.*
FDA Label Image

Figure 2 (Image 02)

Figure 2 (Image 02)
This is a graph showing the mean pain score during a 4-week fixed dose period of Gabapentin (at two different doses) and a placebo among patients. The x-axis represents weeks, and the y-axis represents the mean pain score. There were 7 data points presented, including the baseline score, and the scores at the end of each week.*
FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Cockcroft And Gault Equation (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.